FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1425-1435 April 7, 2005 Number 14 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Pitt, B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD).

Methods A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.

Results The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin (P<0.001). A primary event occurred in 434 patients (8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients (10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001). There was no difference between the two treatment groups in overall mortality.

Conclusions Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.

Source Information

From the State University of New York Health Science Center, Brooklyn (J.C.L.); the University of Texas Southwestern Medical Center, Dallas (S.M.G.); San Francisco General Hospital, San Francisco (D.D.W.); Pfizer, Groton, Conn. (C.S.); the Heart Research Institute, Sydney (P.B.); Institut Pasteur, Lille, France (J.-C.F.); Weill Medical College of Cornell University, New York (A.M.G.); Universitätsklinikum Eppendorf, Hamburg, Germany (H.G.); Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K.); the University of Glasgow, Glasgow, United Kingdom (J.S.); and Emory University School of Medicine, Atlanta (N.K.W.).

This article was published at www.nejm.org on March 8, 2005.

Address reprint requests to Dr. LaRosa at the State University of New York Health Science Center, 450 Clarkson Ave., Brooklyn, NY 11203, or at jclarosa{at}downstate.edu.

Full Text of this Article

Related Letters:

Intensive Lipid Lowering with Atorvastatin in Coronary Disease
Auer J., Lamm G., Eber B., Cannon C. P., Murphy S. A., Braunwald E., Ravnskov U., Rosch P. J., Sutter M. C., Modest G. A., Southern W., LaRosa J. C., Grundy S. M., Waters D. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:93-96, Jul 7, 2005. Correspondence

This article has been cited by other articles:

• Zhu, J., Gardner, J., Pullinger, C. R., Kane, J. P., Thompson, J. F., Francone, O. L. (2009). Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J. Lipid Res. 50: 1330-1339 [Abstract] [Full Text]  
• Phillips, P. S. (2009). Balancing Randomized Trials With Anecdote. ANN INTERN MED 150: 885-886 [Full Text]  
• Miller, M. (2009). Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 0: hcp065v1-hcp065 [Abstract] [Full Text]  
• Leon, M. B., Allocco, D. J., Dawkins, K. D., Baim, D. S. (2009). Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events. J Am Coll Cardiol Intv 2: 504-512 [Abstract] [Full Text]  
• Milionis, H. J., Giannopoulos, S., Kosmidou, M., Panoulas, V., Manios, E., Kyritsis, A. P., Elisaf, M. S., Vemmos, K. (2009). Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology 72: 1816-1822 [Abstract] [Full Text]  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• Schlitt, A., Blankenberg, S., Bickel, C., Lackner, K. J., Heine, G. H., Buerke, M., Werdan, K., Maegdefessel, L., Raaz, U., Rupprecht, H. J., Munzel, T., Jiang, X.-C. (2009). PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. J. Lipid Res. 50: 723-729 [Abstract] [Full Text]  
• Almroth, H., Hoglund, N., Boman, K., Englund, A., Jensen, S., Kjellman, B., Tornvall, P., Rosenqvist, M. (2009). Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 30: 827-833 [Abstract] [Full Text]  
• Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]  
• Thompson, J. F., Hyde, C. L., Wood, L. S., Paciga, S. A., Hinds, D. A., Cox, D. R., Hovingh, G. K., Kastelein, J. J.P. (2009). Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort. Circ Cardiovasc Genet 2: 173-181 [Abstract] [Full Text]  
• Minhas, R, Humphries, S E, Qureshi, N, Neil, H A W, on behalf of the NICE Guideline Development Group, (2009). Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 95: 584-587 [Full Text]  
• Saposnik, G., Goodman, S. G., Leiter, L. A., Yan, R. T., Fitchett, D. H., Bayer, N. H., Casanova, A., Langer, A., Yan, A. T., for the Vascular Protection (VP), , Guidelines-Oriented Approach to Lipid-Lowering (GO, , on behalf of the Stroke Outcome Research Canada (S, (2009). Applying the Evidence: Do Patients With Stroke, Coronary Artery Disease, or Both Achieve Similar Treatment Goals?. Stroke 40: 1417-1424 [Abstract] [Full Text]  
• Laufs, U, Custodis, F, Bohm, M (2009). Who does not need a statin: too late in end-stage renal disease or heart failure?. Postgrad. Med. J. 85: 187-189 [Abstract] [Full Text]  
• Song, S. H, Gray, T. A (2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease 9: 69-74 [Abstract]  
• Alexander, K. P., Blazing, M. A., Rosenson, R. S., Hazard, E., Aronow, W. S., Smith, S. C. Jr, Ohman, E. M. (2009). Management of Hyperlipidemia in Older Adults. J CARDIOVASC PHARMACOL THER 14: 49-58 [Abstract]  
• Sassano, A., Lo Iacono, M., Antico, G., Jordan, A., Uddin, S., Calogero, R. A., Platanias, L. C. (2009). Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Molecular Cancer Therapeutics 8: 615-625 [Abstract] [Full Text]  
• Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A. (2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol 53: 316-322 [Abstract] [Full Text]  
• Dore, D. D., Lapane, K. L., Trivedi, A. N., Mor, V., Weinstock, M. A. (2009). Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. ANN INTERN MED 150: 9-18 [Abstract] [Full Text]  
• SHISHEHBOR, M. H., HAZEN, S. L. (2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine 76: 37-44 [Abstract] [Full Text]  
• Whayne, T. F. Jr (2009). Is There a Problem With Ezetimibe or Just ENHANCEd Hype?. ANGIOLOGY 59: 661-663  
• Mukherjee, R., Locke, K. T., Miao, B., Meyers, D., Monshizadegan, H., Zhang, R., Search, D., Grimm, D., Flynn, M., O'Malley, K. M., Zhang, L., Li, J., Shi, Y., Kennedy, L. J., Blanar, M., Cheng, P. T., Tino, J., Srivastava, R. A. (2008). Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist. J. Pharmacol. Exp. Ther. 327: 716-726 [Abstract] [Full Text]  
• Krasuski, R. A. (2008). Primary Prevention and Statins: Is It Just About Going to Class?. Mayo Clin Proc. 83: 1313-1315 [Full Text]  
• Jacobson, T. A., Wertz, D. A., Hoy, T., Kuznik, A., Grochulski, D., Cziraky, M. (2008). Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clin Proc. 83: 1316-1325 [Abstract] [Full Text]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• van der Hoorn, J. W.A., de Haan, W., Berbee, J. F.P., Havekes, L. M., Jukema, J. W., Rensen, P. C.N., Princen, H. M.G. (2008). Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. Arterioscler. Thromb. Vasc. Bio. 28: 2016-2022 [Abstract] [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J. 84: 590-598 [Abstract] [Full Text]  
• Talelli, P., Greenwood, R. J. (2008). Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. Ther Adv Cardiovasc Dis 2: 387-405 [Abstract]  
• Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. (2008). Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol 52: 914-920 [Abstract] [Full Text]  
• Boekholdt, S. M., de Winter, R. J., Kastelein, J. J.P. (2008). Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib: Shifting Gears in Cardiovascular Drug Development: Are Antiinflammatory Drugs the Next Frontier?. Circulation 118: 1120-1122 [Full Text]  
• Newman, C. B, Szarek, M., Colhoun, H. M, Betteridge, D J., Durrington, P. N, Hitman, G. A, Neil, H A. W, Demicco, D. A, Auster, S., Fuller, J. H (2008). The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research 5: 177-183 [Abstract]  
• Laufs, U, Custodis, F, Bohm, M (2008). Who does not need a statin: too late in end-stage renal disease or heart failure?. Heart 94: 1138-1140 [Abstract] [Full Text]  
• The SEARCH Collaborative Group, (2008). SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study. NEJM 359: 789-799 [Abstract] [Full Text]  
• Zoghbi, G. J., Dorfman, T. A., Iskandrian, A. E. (2008). The Effects of Medications on Myocardial Perfusion. J Am Coll Cardiol 52: 401-416 [Abstract] [Full Text]  
• Steinberg, D., Glass, C. K., Witztum, J. L. (2008). Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. Circulation 118: 672-677 [Full Text]  
• Shepherd, J., Kastelein, J. J. P., Bittner, V. A., Carmena, R., Deedwania, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., Wenger, N. K., Treating to New Targets Steering Committee and Inv, (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease. Mayo Clin Proc. 83: 870-879 [Abstract] [Full Text]  
• Filippatos, T. D., Mikhailidis, D. P. (2008). Statins and Heart Failure. ANGIOLOGY 59: 58S-61S [Abstract]  
• Settergren, M., Bohm, F., Ryden, L., Pernow, J. (2008). Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753-1760 [Abstract] [Full Text]  
• White, J. R. Jr (2008). Do People With Diabetes Need Statins?. The Diabetes Educator 34: 664-673 [Abstract] [Full Text]  
• Pedersen, T. R. (2008). Overview of clinical trials on calcific aortic stenosis. Eur Heart J Suppl 10: E31-E40 [Abstract] [Full Text]  
• Kastelein, J. J.P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., Grundy, S. M., for the TNT and IDEAL Study Groups, (2008). Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation 117: 3002-3009 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P., Szarek, M., Callahan, A. III, Hennerici, M., Sillesen, H., Zivin, J. A., Welch, K.M.A., On behalf of the SPARCL Investigators, (2008). Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70: 2364-2370 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94: 706-714 [Abstract] [Full Text]  
• Shah, S. J., Waters, D. D., Barter, P., Kastelein, J. J.P., Shepherd, J., Wenger, N. K., DeMicco, D. A., Breazna, A., LaRosa, J. C. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. J Am Coll Cardiol 51: 1938-1943 [Abstract] [Full Text]  
• Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., Rader, D. J. (2008). The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. J Am Coll Cardiol 51: 1653-1662 [Abstract] [Full Text]  
• Ambrose, J. A. (2008). In Search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention?. J Am Coll Cardiol 51: 1539-1542 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the TNT (Treating to New Targets) Investigator, (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol 51: 1448-1454 [Abstract] [Full Text]  
• Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]  
• Torabi, A., Cleland, J. G.F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J. L., Rigby, A. S., Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 29: 859-870 [Abstract] [Full Text]  
• Arca, M., Conti, B., Montali, A., Pignatelli, P., Campagna, F., Barilla, F., Tanzilli, G., Verna, R., Vestri, A., Gaudio, C., Violi, F. (2008). C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease. Arterioscler. Thromb. Vasc. Bio. 28: 752-757 [Abstract] [Full Text]  
• Wenger, N K, Lewis, S J, Welty, F K, Herrington, D M, Bittner, V, on behalf of the TNT Steering Committee and Invest, (2008). Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 94: 434-439 [Abstract] [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Birnbaum, Y., Lin, Y., Ye, Y., Merla, R., Perez-Polo, J. R., Uretsky, B. F. (2008). Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat. J CARDIOVASC PHARMACOL THER 13: 72-79 [Abstract]  
• Josan, K. MD, Majumdar, S. R. MD MPH, McAlister, F. A. MD MSc (2008). The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576-584 [Abstract] [Full Text]  
• Bittner, V., Herrington, D., Wenger, N. (2008). Analyzing the Results of the Treating to New Targets Study. ANN INTERN MED 148: 322-323 [Full Text]  
• Donner-Banzhoff, N., Sonnichsen, A. (2008). Strategies for prescribing statins. BMJ 336: 288-289 [Full Text]  
• Zannad, F., Stough, W. G., Pitt, B., Cleland, J. G.F., Adams, K. F., Geller, N. L., Torp-Pedersen, C., Kirwan, B.-A., Follath, F. (2008). Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 29: 413-421 [Abstract] [Full Text]  
• Richards, N., Harris, K., Whitfield, M., O'Donoghue, D., Lewis, R., Mansell, M., Thomas, S., Townend, J., Eames, M., Marcelli, D. (2008). Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 23: 549-555 [Abstract] [Full Text]  
• Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.. J Am Coll Cardiol 51: 449-455 [Abstract] [Full Text]  
• Superko, H. R., King, S. III (2008). Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. Circulation 117: 560-568 [Full Text]  
• Grundy, S. M. (2008). Promise of Low-Density Lipoprotein-Lowering Therapy for Primary and Secondary Prevention. Circulation 117: 569-573 [Full Text]  
• Grundy, S. M. (2008). Thyroid mimetic as an option for lowering low-density lipoprotein. Proc. Natl. Acad. Sci. USA 105: 409-410 [Full Text]  
• Nesto, R. W. (2008). LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. Clin. Diabetes 26: 8-13 [Abstract] [Full Text]  
• Anand, D. V., Lim, E., Darko, D., Bassett, P., Hopkins, D., Lipkin, D., Corder, R., Lahiri, A. (2007). Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes: Role of Glycemic Control and Inflammatory/Vascular Calcification Markers. J Am Coll Cardiol 50: 2218-2225 [Abstract] [Full Text]  
• Holman, J. R. (2007). Some Docs in Denial About Statin Side Effects. DOC News 4: 1-12 [Full Text]  
• Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., Gillen, D. (2007). A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. J Clin Pharmacol 47: 1555-1569 [Abstract] [Full Text]  
• Chaturvedi, S., Turan, T. N., Lynn, M. J., Kasner, S. E., Romano, J., Cotsonis, G., Frankel, M., Chimowitz, M. I., For the WASID Study Group, (2007). Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69: 2063-2068 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the Treating to New Targets Investigators, (2007). Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study. CJASN 2: 1131-1139 [Abstract] [Full Text]  
• Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., Kwiterovich, P. O. Jr (2007). Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. J Am Coll Cardiol 50: 1735-1741 [Abstract] [Full Text]  
• Marschner, I. C., Simes, R. J., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. Am J Epidemiol 166: 824-831 [Abstract] [Full Text]  
• Cahoon, W. D Jr, Crouch, M. A (2007). Preprocedural Statin Therapy in Percutaneous Coronary Intervention. The Annals of Pharmacotherapy 41: 1687-1693 [Abstract] [Full Text]  
• Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J.P., Bittner, V., Fruchart, J.-C., the Treating to New Targets Investigators, (2007). HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. NEJM 357: 1301-1310 [Abstract] [Full Text]  
• Blanco, M., Nombela, F., Castellanos, M., Rodriguez-Yanez, M., Garcia-Gil, M., Leira, R., Lizasoain, I., Serena, J., Vivancos, J., Moro, M. A., Davalos, A., Castillo, J. (2007). Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 69: 904-910 [Abstract] [Full Text]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• Stein, E. A. (2007). Statins and Children: Whom Do We Treat and When?. Circulation 116: 594-595 [Full Text]  
• Leeper, N. J., Ardehali, R., deGoma, E. M., Heidenreich, P. A. (2007). Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival. Circulation 116: 613-618 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]  
• Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K. (2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93: 933-939 [Abstract] [Full Text]  
• Choudhry, N. K, Levin, R., Winkelmayer, W. C (2007). Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 93: 945-951 [Abstract] [Full Text]  
• Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., Karas, R. H. (2007). Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials. J Am Coll Cardiol 50: 409-418 [Abstract] [Full Text]  
• Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., for the Treating to New Targets Study Steering Com, (2007). Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. ANN INTERN MED 147: 1-9 [Abstract] [Full Text]  
• Brewster, L. M., van Montfrans, G. A. (2007). Letter by Brewster and van Montfrans Regarding Article, "Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials". Circulation 116: e7-e7 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Nogueira, J., Weir, M. (2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN 2: 766-785 [Abstract] [Full Text]  
• Timmis, A. D, Feder, G., Hemingway, H. (2007). Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution. Heart 93: 786-791 [Abstract] [Full Text]  
• Kostapanos, M.S., Liberopoulos, E.N., Goudevenos, J.A., Mikhailidis, D.P., Elisaf, M.S. (2007). Do statins have an antiarrhythmic activity?. Cardiovasc Res 75: 10-20 [Abstract] [Full Text]